O'Hanlon J F, Vermeeren A, Uiterwijk M M, van Veggel L M, Swijgman H F
Institute for Human Psychopharmacology, University of Limburg, Maastricht, The Netherlands.
Neuropsychobiology. 1995;31(2):81-8. doi: 10.1159/000119177.
Effects of benzodiazepine (diazepam, lorazepam) and benzodiazepine-like anxiolytics (alpidem, suriclone) and a 5-HT-3 antagonist (ondansetron) on actual driving performance were measured in three double-blind, placebo-controlled studies. Subjects were healthy volunteers in two and anxious patients in the third. Treatments lasted for 8 days. Standardized testing occurred within the first full day and on the last day of treatment. No important differences existed between volunteers' and patients' baseline and/or placebo performances and both groups responded similarly to comparable drugs/doses. Benzodiazepine and benzodiazepine-like anxiolytics produced marked and pervasive driving impairment, which lasted throughout treatment; but ondansetron, none.
在三项双盲、安慰剂对照研究中，测定了苯二氮䓬类药物（地西泮、劳拉西泮）、苯二氮䓬类抗焦虑药（阿吡坦、舒氯克隆）以及5-羟色胺-3拮抗剂（昂丹司琼）对实际驾驶性能的影响。在两项研究中受试者为健康志愿者，在第三项研究中为焦虑症患者。治疗持续8天。在治疗的第一个完整日和最后一日进行标准化测试。志愿者和患者的基线和/或安慰剂表现之间不存在重要差异，两组对相当的药物/剂量反应相似。苯二氮䓬类药物和苯二氮䓬类抗焦虑药产生了明显且普遍的驾驶能力损害，这种损害在整个治疗期间持续存在；但昂丹司琼没有这种情况。
